These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3198006)

  • 1. Markers for faecal fat estimation in monitoring steatorrhoea in cystic fibrosis.
    Gilbert J; Kelleher J; Walters MP; Littlewood JM
    Gut; 1988 Sep; 29(9):1286-8. PubMed ID: 3198006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of enteric coated microspheres with enteric coated tablet pancreatic enzyme preparations in cystic fibrosis. A controlled study.
    Vyas H; Matthew DJ; Milla PJ
    Eur J Pediatr; 1990 Jan; 149(4):241-3. PubMed ID: 1689245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical monitoring of steatorrhoea in cystic fibrosis.
    Walters MP; Kelleher J; Gilbert J; Littlewood JM
    Arch Dis Child; 1990 Jan; 65(1):99-102. PubMed ID: 2301990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of taurine supplementation on fat and energy absorption in cystic fibrosis.
    De Curtis M; Santamaria F; Ercolini P; Vittoria L; De Ritis G; Garofalo V; Ciccimarra F
    Arch Dis Child; 1992 Sep; 67(9):1082-5. PubMed ID: 1417050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enteric coated microspheres of pancreatin in the treatment of cystic fibrosis: comparison with a standard enteric coated preparation.
    Stead RJ; Skypala I; Hodson ME; Batten JC
    Thorax; 1987 Jul; 42(7):533-7. PubMed ID: 3326213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of steatorrhoea in cystic fibrosis: a comparison of enteric-coated microspheres of pancreatin versus non-enteric-coated pancreatin and adjuvant cimetidine.
    Stead RJ; Skypala I; Hodson ME
    Aliment Pharmacol Ther; 1988 Dec; 2(6):471-82. PubMed ID: 2979269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radio-opaque pellets as faecal markers for faecal fat estimation in malabsorption.
    Simpson FG; Hall GP; Kelleher J; Losowsky MS
    Gut; 1979 Jul; 20(7):581-4. PubMed ID: 488754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring steatorrhoea in cystic fibrosis.
    De Curtis M; Santamaria F; Ercolini P; Sica G; Bianco V; Ciccimarra F
    Eur J Pediatr; 1994 Jun; 153(6):416-8. PubMed ID: 8088296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic enzyme replacement therapy. Importance of gastric acid secretion, H2-antagonists, and enteric coating.
    Marotta F; O'Keefe SJ; Marks IN; Girdwood A; Young G
    Dig Dis Sci; 1989 Mar; 34(3):456-61. PubMed ID: 2563963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of acid steatocrit.
    Van den Neucker A; Pestel N; Tran TM; Forget PP; Veeze HJ; Bouquet J; Sinaasappel M
    Acta Paediatr; 1997 May; 86(5):466-9. PubMed ID: 9183483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of bile acid loss in cystic fibrosis by dietary means.
    Smalley CA; Brown GA; Parkes ME; Tease H; Brookes V; Anderson CM
    Arch Dis Child; 1978 Jun; 53(6):477-82. PubMed ID: 686773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of weight-based dosages of enteric-coated microtablet enzyme preparations in patients with cystic fibrosis.
    Beker LT; Fink RJ; Shamsa FH; Chaney HR; Kluft J; Evans E; Schidlow DV
    J Pediatr Gastroenterol Nutr; 1994 Aug; 19(2):191-7. PubMed ID: 7815242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of enteric-coated preparations on nutritional parameters in cystic fibrosis. A long-term study.
    Carroccio A; Pardo F; Montalto G; Japichino L; Iacono G; Collura M; Notarbartolo A
    Digestion; 1988; 41(4):201-6. PubMed ID: 3243379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxalate-loading tests to screen for steatorrhoea: an appraisal.
    Foster PN; Will EJ; Kelleher J; Losowsky MS
    Clin Chim Acta; 1984 Dec; 144(2-3):155-61. PubMed ID: 6529853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enteric-coated pancreatic enzyme with bicarbonate is equal to standard enteric-coated enzyme in treating malabsorption in cystic fibrosis.
    Kalnins D; Ellis L; Corey M; Pencharz PB; Stewart C; Tullis E; Durie PR
    J Pediatr Gastroenterol Nutr; 2006 Mar; 42(3):256-61. PubMed ID: 16540792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New modalities in the treatment of exocrine pancreatic insufficiency in cystic fibrosis.
    Heijerman HG
    Neth J Med; 1992 Oct; 41(3-4):105-9. PubMed ID: 1470278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faecal weight and the fat content.
    Chatterjee S; Bhattacharyya AK; Mandal JN
    Bull Calcutta Sch Trop Med; 1967 Jul; 15(3):98-9. PubMed ID: 5616304
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic potential and clinical efficacy of acid-resistant fungal lipase in the treatment of pancreatic steatorrhoea due to cystic fibrosis.
    Zentler-Munro PL; Assoufi BA; Balasubramanian K; Cornell S; Benoliel D; Northfield TC; Hodson ME
    Pancreas; 1992; 7(3):311-9. PubMed ID: 1594552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excessive faecal losses of vitamin A (retinol) in cystic fibrosis.
    Ahmed F; Ellis J; Murphy J; Wootton S; Jackson AA
    Arch Dis Child; 1990 Jun; 65(6):589-93. PubMed ID: 2378514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of fat malabsorption.
    Teh LB; Stopard M; Anderson S; Grant A; Quantrill D; Wilkinson RH; Jewell DP
    J Clin Pathol; 1983 Dec; 36(12):1362-6. PubMed ID: 6655068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.